Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model

Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the... Background A critical component of the host defense against enteric infections is the immunological response of the mucosal membrane, a major starting point of infectious disease, such as typhoid fever. The mucosal immune system consists of an integrated network of lymphoid tissues, mucous membrane‐associated cells, and effector molecules. In the present study, we developed a recombinant Bifidobacterium animalis (B. animalis) genetically modified with the Salmonella flagellin gene for mucosal immunization as an oral typhoid vaccine. Methods We constructed an oral vaccine against Salmonella typhimurium, consisting of recombinant B. animalis containing the flagellin gene of Salmonella. The recombinant B. animalis was administered orally to mice every other day for 6 weeks. Anti‐flagellin antibodies in the serum and stools were measured by enzyme‐linked immunosorbent assay (ELISA). Results We detected significantly higher levels of flagellin‐specific IgA in the serum and stools of the mice treated with the recombinant B. animalis containing the flagellin gene than was seen in those treated with parental B. animalis. Conclusions Our findings suggest that an oral vaccination using recombinant B. animalis genetically modified with the flagellin gene of Salmonella may be effective against Salmonella infections. Copyright © 2006 John Wiley & Sons, Ltd. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Gene Medicine Wiley

Genetically engineered Bifidobacterium animalis expressing the Salmonella flagellin gene for the mucosal immunization in a mouse model

Loading next page...
 
/lp/wiley/genetically-engineered-bifidobacterium-animalis-expressing-the-eOLsCWMG21

References (29)

Publisher
Wiley
Copyright
Copyright © 2006 John Wiley & Sons, Ltd.
ISSN
1099-498X
eISSN
1521-2254
DOI
10.1002/jgm.963
pmid
16958059
Publisher site
See Article on Publisher Site

Abstract

Background A critical component of the host defense against enteric infections is the immunological response of the mucosal membrane, a major starting point of infectious disease, such as typhoid fever. The mucosal immune system consists of an integrated network of lymphoid tissues, mucous membrane‐associated cells, and effector molecules. In the present study, we developed a recombinant Bifidobacterium animalis (B. animalis) genetically modified with the Salmonella flagellin gene for mucosal immunization as an oral typhoid vaccine. Methods We constructed an oral vaccine against Salmonella typhimurium, consisting of recombinant B. animalis containing the flagellin gene of Salmonella. The recombinant B. animalis was administered orally to mice every other day for 6 weeks. Anti‐flagellin antibodies in the serum and stools were measured by enzyme‐linked immunosorbent assay (ELISA). Results We detected significantly higher levels of flagellin‐specific IgA in the serum and stools of the mice treated with the recombinant B. animalis containing the flagellin gene than was seen in those treated with parental B. animalis. Conclusions Our findings suggest that an oral vaccination using recombinant B. animalis genetically modified with the flagellin gene of Salmonella may be effective against Salmonella infections. Copyright © 2006 John Wiley & Sons, Ltd.

Journal

Journal of Gene MedicineWiley

Published: Nov 1, 2006

Keywords: Bifidobacterium animalis ; mucosal vaccine; Salmonella typhimurium ; flagellin

There are no references for this article.